http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Ionis licenses investigational Alzheimer's therapy
-
Akcea Retains Rights to AKCEA-APOCIII-LRx
-
Akcea Retains Rights to AKCEA-APOCIII-LRx
-
Ionis Pharmaceuticals (IONS) appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
-
Ionis appoints C. Frank Bennett, Ph.D., to chief scientific officer and promotes Eric E. Swayze, Ph.D., to senior vice president of research
-
Akcea Therapeutics (AKCA) Announces Lynne Parshall, J.D. as Bpard Chair; Appoints Barbara Yanni to Board
-
Akcea Therapeutics Announces New Appointments to its Board of Directors
-
Akcea Therapeutics Announces New Appointments to its Board of Directors
-
Akcea Announces Appointment of New Chief Operating Officer
-
Akcea Announces Appointment of New Chief Operating Officer
-
Ionis Pharmaceuticals to hold technology webcast
-
Akcea Therapeutics (AKCA), Ionis Pharmaceuticals, Inc. (IONS) Commence NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx
-
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
-
Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR Amyloidosis
-
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
-
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Akcea Therapeutics to Present at Upcoming Investor Conferences
-
Ionis Pharmaceuticals to present at upcoming investor conferences
-
Ionis provides third quarter financial results and improved 2019 guidance
-
Akcea Reports Financial Results and Highlights for Third Quarter 2019
-
Akcea Reports Financial Results and Highlights for Third Quarter 2019
-
Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
-
Akcea Recognizes Landmark Year for Familial Chylomicronemia Syndrome (FCS) Community with Commemoration of 2nd Annual FCS Awareness Day
-
Bench to bedside strategies demonstrate Ionis' foremost expertise in RNA-targeted therapeutics at DIA/FDA Oligonucleotide Conference
-
Ionis Chairman and CEO Stanley T. Crooke, M.D., Ph.D. to receive Massry Prize for contributions to biomedical sciences
-
Akcea Announces Appointment of New Chief Commercial Officer
-
Akcea Announces Appointment of New Chief Commercial Officer
-
Ionis Pharmaceuticals to hold third quarter 2019 financial results webcast
-
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
-
Akcea Therapeutics to Hold Third Quarter 2019 Financial Results Webcast
-
Ionis' leadership in RNA-targeted therapeutics recognized at the Oligonucleotide Therapeutics Society annual meeting
-
Ionis' (IONS) Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
-
Ionis' Factor XI anti-thrombotic medicine advances with Bayer following positive clinical results
-
Akcea Therapeutics (AKCA), Pfizer (PFE) Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
-
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
-
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)
-
Biogen (BIIB) Announces Landmark NURTURE Study of Infants with SMA Treated Pre-Symptomatically with SPINRAZA Published in Neuromuscular Disorders
-
Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in Neuromuscular Disorders
-
Ionis to receive the CLSA's 2019 Pantheon DiNA™ Award for Company of the Year
-
Akcea Therapeutics (AKCA) Reports Election of Michael J. Yang and Joseph ‘Skip’ Klein III to Board
-
Akcea Announces CEO Transition and Elects Two New Board Members
-
Biogen (BIIB) Reports Initiation of New Global Clinical Trial, DEVOTE, Evaluating Higher Dose of SPINRAZA (nusinersen) & Additional Data
-
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
-
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and Additional Data in a Broad Range of Patients
-
Akcea Therapeutics (AKCA) Reports Positive Phase 1 Results of AKCEA-TTR-LRx
-
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
-
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual Meeting
-
Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings
-
Akcea and Ionis to Present New Data for TEGSEDI and AKCEA-TTR-LRx at Two Upcoming Medical Meetings

